EGFR and pneumonitis: ILD is a frequent comorbidity in lung cancer and can also be induced by anticancer therapies, including epidermal growth factor receptor inhibitors.43,44 As a significant and potentially fatal adverse reaction, ILD requires careful monitoring, especially in patients with risk factors, such as pre-existing ILD/pneumonitis, or recent prior immunotherapy or thoracic radiotherapy.45